{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-194428","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.761882+00:00","generated_at":"2026-05-31T12:33:25.452868+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sensei Biotherapeutics Q2 net loss $7.1M; cash $52.3M; SNS-101 dose expansion on track","bullets":["Net loss $7.1M vs $9.4M in Q2 2023; R&D $4.6M (-$0.2M), G&A $3.2M (-$2.2M).","Cash $52.3M, expected to fund operations into Q4 2025.","Phase 1/2 SNS-101 dose expansion enrollment advancing; initial data Q4 2024; end-of-Phase 1 FDA meeting by year-end.","ASCO 2024 data showed well-tolerated safety, best-in-class PK, and early clinical activity.","Appointed Josiah Craver as SVP of Finance, effective July 22, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-194428","json":"https://secwatch.observer/filing/0001193125-24-194428.json","markdown":"https://secwatch.observer/filing/0001193125-24-194428.md","text":"https://secwatch.observer/filing/0001193125-24-194428.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/0001193125-24-194428-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312524194428/d862389d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:33:25.452868+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}